
    
      The purpose of this study is to evaluate the effects of EPI-743 in patient with Leigh
      syndrome on disease severity, neuromuscular function, respiratory function, disease morbidity
      and mortality and biomarkers associated with the disease.

      This study is a six month prospective randomized double-blind, placebo-controlled trial with
      a six month extension phase of two dose levels of EPI743. The planned enrollment is for
      approximately 30 children with genetically confirmed Leigh syndrome. After 6 months of
      treatment, those children that were randomized to the placebo treatment arm will be
      re-randomized to one of the 2 active treatment arms.
    
  